Description: Mylan, the maker of the allergy treatment EpiPen, said Friday that it had reached a $465 million settlement with the Justice Department and other government agencies over questions on whether the company had overcharged Medicaid for the treatment by improperly classifying it as a generic drug.
Date: Oct 08, 2016
Questions for discussion:
- What does the report say about Mylan’s practices and the settlement announced?
- Do you believe there was no wrongdoing?
- How should shareholders deal with management of the firm?